JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a price target of $80.
June 04, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating for Crinetics Pharmaceuticals and maintained a price target of $80, indicating strong confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $80 by JMP Securities suggests strong confidence in Crinetics Pharmaceuticals' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100